Needham analyst Alan Carr assigned a Buy rating to Crispr Therapeutics AG (CRSP) today and set a price target of $105.00. The company’s shares closed last Monday at $92.12, close to its 52-week high of $97.82.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.5% and a 42.0% success rate. Carr covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, ACADIA Pharmaceuticals, and Vertex Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Crispr Therapeutics AG with a $95.39 average price target, implying a 4.5% upside from current levels. In a report issued on July 14, SunTrust Robinson also initiated coverage with a Buy rating on the stock with a $140.00 price target.
See today’s analyst top recommended stocks >>
Crispr Therapeutics AG’s market cap is currently $6.33B and has a P/E ratio of 118.90. The company has a Price to Book ratio of 7.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
Read More on CRSP:
